Silexion Therapeutics's total assets for Q were $3.58M, a decrease of -31.79% from the previous quarter. SLXN total liabilities were $1.98M for the fiscal quarter, a -12.42% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.